CORRECT Study of Minimal Residual Disease Detection in Colorectal Cancer
The CORRECT - MRD II study will prospectively enroll patients who have undergone complete surgical resection for stage II or III colorectal cancer. Patients will be followed for a minimum of 3 years and up to 5 years for recurrence.
Colorectal Cancer
DEVICE: MRD
To validate the association of circulating tumor DNA (ctDNA) with recurrence-free interval (RFI)., 7 years
To assess the sensitivity and specificity of ctDNA positivity for subsequent clinical recurrence., 7 years|To assess the contribution of ctDNA on RFI, independent of clinicopathological risk features and other biomarkers, 7 years|To assess time from positive ctDNA to clinical recurrence, 7 years
The CORRECT - MRD II study will prospectively enroll patients who have undergone complete surgical resection for stage II or III colorectal cancer. Patients will be followed for a minimum of 3 years and up to 5 years for recurrence.